Skye Bioscience Inc.(SKYE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SKYE Skye Bioscience Inc.

Trading 01-27 14:28:01 EST

1.01

-0.01

-0.97%

High1.06	Low1.01	Vol89.23K
Open1.03	D1 Closing1.02	Amplitude4.89%
Mkt Cap32.38M	Tradable Cap19.89M	Total Shares32.06M
T/O92.96K	T/O Rate0.45%	Tradable Shares19.69M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SKYE","market":"US","secType":"STK","nameCN":"Skye Bioscience Inc.","latestPrice":1.0101,"timestamp":1769541536884,"preClose":1.02,"halted":0,"volume":89231,"delay":0,"changeRate":-0.009705882352941196,"floatShares":19689100,"shares":32057500,"eps":-1.291415,"marketStatus":"Trading","change":-0.0099,"latestTime":"01-27 14:28:01 EST","open":1.03,"high":1.06,"low":1.0101,"amount":92963.73796130001,"amplitude":0.048922,"askPrice":1.03,"askSize":205,"bidPrice":1.02,"bidSize":43,"shortable":3,"etf":0,"ttmEps":-1.291415,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1769547600000},"marketStatusCode":2,"symbolChange":{"newSymbol":"SKYED","executeDate":"2023-09-08"},"adr":0,"exchange":"NASDAQ","adjPreClose":1.02,"preHourTrading":{"tag":"盘前","latestPrice":1.0484,"preClose":1.02,"latestTime":"08:55 EST","volume":1568,"amount":1616.1876192,"timestamp":1769522131952,"change":0.0284,"changeRate":0.027843,"amplitude":0.038725},"postHourTrading":{"tag":"盘后","latestPrice":1.02,"preClose":1.02,"latestTime":"19:10 EST","volume":996,"amount":1010.23,"timestamp":1769472617923,"change":0,"changeRate":0,"amplitude":0.019608},"volumeRatio":0.707912,"impliedVol":1.1162,"impliedVolPercentile":0.247},"requestUrl":"/m/hq/s/SKYE","defaultTab":"news","newsList":[{"id":"2605673101","title":"Skye Bioscience Launches Phase 2a Trial of Nimacimab for Obesity Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2605673101","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605673101?lang=en_us&edition=fundamental","pubTime":"2026-01-21 20:00","pubTimestamp":1768996841,"startTime":"0","endTime":"0","summary":"Skye Bioscience Inc. has announced the presentation of new research on its peripherally-restricted CB1-inhibitor antibody, nimacimab, at the Keystone Obesity Therapeutics conference. The study investigates nimacimab’s efficacy alone, in combination with tirzepatide, and as a maintenance therapy following tirzepatide discontinuation in a diet-induced obesity mouse model. The research also examines whether caloric restriction is the primary mechanism behind nimacimab-driven weight loss. Results from this study are scheduled to be presented on January 28, 2026, during Poster Session 2 . Nimacimab is being developed as a potential first-in-class therapeutic for obesity and metabolic health disorders, and is currently being evaluated in a Phase 2a clinical trial for obesity.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purp","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDL1cwDHF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","IE00B64PRP62.GBP","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","SG9999014013.SGD","LU2095319765.USD","BK4585","BK4112","LU2210150020.SGD","BK4588","SG9999014005.SGD","SG9999014021.USD","BK4139","IE00BKPKM429.USD","LU2210149790.SGD","NDAQ","SG9999014039.USD"],"gpt_icon":0},{"id":"2603883979","title":"Analysts Offer Insights on Healthcare Companies: TNL Mediagene (TNMG) and Skye Bioscience (SKYE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603883979","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603883979?lang=en_us&edition=fundamental","pubTime":"2026-01-15 21:10","pubTimestamp":1768482649,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on TNL Mediagene (TNMG – Research Report) and Skye Bi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-tnl-mediagene-tnmg-and-skye-bioscience-skye-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-tnl-mediagene-tnmg-and-skye-bioscience-skye-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4581","BK4137","TNL","BK4585","XBI","BK4142","LU0128526141.USD","LABU","XLV","BK4588","LU0029874061.USD","SKYE","HCSG"],"gpt_icon":0},{"id":"2602514197","title":"Skye Bioscience to Launch Phase 2b Trial of Nimacimab for Obesity in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602514197","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602514197?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:02","pubTimestamp":1768219357,"startTime":"0","endTime":"0","summary":"Skye Bioscience Inc. has announced its 2026 corporate outlook, detailing upcoming clinical milestones for its peripherally restricted CB1-inhibiting antibody, nimacimab, aimed at treating obesity and metabolic health disorders. Key clinical objectives for 2026 include an interim data update from the CBeyond Phase 2a 26-week extension, expected in the first quarter of 2026, and topline results covering 52 weeks with a 13-week off-therapy follow-up period, anticipated in the third quarter of 2026. Additionally, the company plans to finalize and initiate a Phase 2b  adaptive design clinical trial in the third quarter of 2026, following alignment with regulators. These results have not yet been presented and are expected in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL6jg2XL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SG9999014021.USD","LU0314104364.USD","BK4588","BK4112","IE00B3QW5Z07.USD","LU2210149790.SGD","NDAQ","BK4139","LU2210150020.SGD","SG9999014039.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SKYE","LU2095319765.USD","SG9999014013.SGD","IE00BKPKM429.USD","SG9999014005.SGD"],"gpt_icon":0},{"id":"2602514546","title":"Skye Provides 2026 Corporate Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2602514546","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602514546?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219203,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUACXQ1R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SKYE"],"gpt_icon":0},{"id":"2602046514","title":"Skye Bioscience Inc - Phase 2B Cbeyond 2 Trial Launch Targeted for Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602046514","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602046514?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219203,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUACXQ1R:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2602040514","title":"Skye Bioscience Inc - Cbeyond Phase 2a Topline Results Expected Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602040514","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602040514?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219203,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUACXQ1R:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SKYE"],"gpt_icon":0},{"id":"2601853672","title":"Investors File Class Action Lawsuit Against Skye Bioscience","url":"https://stock-news.laohu8.com/highlight/detail?id=2601853672","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601853672?lang=en_us&edition=fundamental","pubTime":"2026-01-06 07:00","pubTimestamp":1767654022,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against Skye Bioscience Inc. on behalf of investors who claim to have suffered losses due to alleged securities fraud between November 4, 2024 and October 3, 2025. The case is being handled by the law firm Levi & Korsinsky, which has a history of representing shareholders in securities litigation. Investors who incurred losses during the specified period are encouraged to seek more information and consider joining the class action.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief via ACCESS Newswire  on January 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL4T1D8f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2601313638","title":"BUZZ-U.S. STOCKS ON THE MOVE-Synchrony Financial, Coinbase, Versant Media Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2601313638","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601313638?lang=en_us&edition=fundamental","pubTime":"2026-01-06 02:47","pubTimestamp":1767638851,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Synchrony Financial, Coinbase, Versant Media Group Eikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nL6N3Y60J1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRNX","OKTA","WMB","QXO","SPIR","OMC","HL","GHRS","LBRT","EOG","SLB","RIOT","NOC","COP","EBC","MPC","HCA","AVY","RMTI","SKYE","SYF","BAC","ANET","HAL","BKR","ALT","CNX","DPZ","MBLY","CVS","INCY","CNC","LMT","SATL","LCID","AVAV","BKSY","NEM","ALB","SCCO"],"gpt_icon":1},{"id":"2601460882","title":"BUZZ-U.S. STOCKS ON THE MOVE-Alphabet, Liberty Energy, Fortive","url":"https://stock-news.laohu8.com/highlight/detail?id=2601460882","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601460882?lang=en_us&edition=fundamental","pubTime":"2026-01-05 22:14","pubTimestamp":1767622447,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Alphabet, Liberty Energy, Fortive Eikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter:","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nL6N3Y60JN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COP","RIOT","NEM","FIVN","DUOL","GOOGL","HAL","OKTA","ALT","IBM","OMC","SLB","BKSY","EOG","SATL","SPIR","EBC","ALRS","SCCO","SGHT","MBLY","FTV","THC","BKR","HL","KBR","ALB","ANET","AZO","HCA","CDE","RMTI","ARDT","STX","NMRA","DVN","LBRT","INCY","SKYE","GHRS"],"gpt_icon":1},{"id":"2601788664","title":"BUZZ-Skye Bioscience rises as it partners with Halozyme on obesity drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2601788664","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601788664?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:13","pubTimestamp":1767615228,"startTime":"0","endTime":"0","summary":"BUZZ-Skye Bioscience rises as it partners with Halozyme on obesity drug** Shares of drug developer Skye Bioscience SKYE.O rise 4.76% to $0.92 premarket** Co says it has signed a global agreement with Halozyme Therapeutics HALO.O to develop and potentially commercialize a new obesity treatment** SKYE says deal will develop injectable version of nimacimab, an experimental obesity drug** Nimacimab aims to help with weight loss; study to test combo with GLP-1 drugs already used for obesity - SKYE** Co plans mid-stage trial of new formulation in mid-2026** Halozyme to get milestone payments and royalties if drug is approved and launched - SKYE** As of last close, stock up ~17% over the past year  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nL4N3Y60SD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0053671581.USD","SKYE","HALO"],"gpt_icon":0},{"id":"2601885098","title":"Skye Bioscience Inc:  Skye Is Planning to Initiate a Phase 2B Clinical Trial in Obesity for Nimacimab With Enhanze in Middle of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601885098","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601885098?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:00","pubTimestamp":1767614418,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nFWN3Y60HA:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HALO","LU0053671581.USD","SKYE","BK4139"],"gpt_icon":0},{"id":"2601885793","title":"Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated With Enhanze® for Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2601885793","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601885793?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:00","pubTimestamp":1767614403,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUA2R2D2B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SKYE","LU0053671581.USD","HALO","BK4139"],"gpt_icon":0},{"id":"2601588503","title":"Halozyme Therapeutics Inc - Skye Plans Phase 2B Trial for Nimacimab in Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601588503","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601588503?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:00","pubTimestamp":1767614403,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUA2R2D2B:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SKYE","BK4139","LU0053671581.USD","HALO"],"gpt_icon":0},{"id":"2593448072","title":"Skye Bioscience Inc - on Dec 18, Enters Collaboration Agreement With Halozyme - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2593448072","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593448072?lang=en_us&edition=fundamental","pubTime":"2025-12-24 05:07","pubTimestamp":1766524025,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nFWN3XT0P9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SKYE"],"gpt_icon":0},{"id":"2593544806","title":"Skye Bioscience Signs Collaboration and License Agreement with Halozyme","url":"https://stock-news.laohu8.com/highlight/detail?id=2593544806","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593544806?lang=en_us&edition=fundamental","pubTime":"2025-12-24 05:05","pubTimestamp":1766523910,"startTime":"0","endTime":"0","summary":"Skye Bioscience Inc. announced that it has entered into a Non-exclusive Collaboration and License Agreement with Halozyme, Inc. Under the agreement, Skye Bioscience will receive a non-exclusive license to Halozyme's ENHANZE drug delivery technology for the development of a subcutaneous formulation of nimacimab. Halozyme will be the exclusive supplier of clinical and commercial supplies of the rHuPH20 bulk drug product for Skye Bioscience. The agreement includes milestone payments tied to development and commercialization events, as well as royalty payments based on worldwide net sales of the product.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief via E","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL2qfW9V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","HALO","LU0053671581.USD","BK4139"],"gpt_icon":0},{"id":"2593041068","title":"Investors File Class Action Lawsuit Against Skye Bioscience Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2593041068","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593041068?lang=en_us&edition=fundamental","pubTime":"2025-12-24 03:42","pubTimestamp":1766518942,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against Skye Bioscience Inc. on behalf of investors who suffered losses due to alleged securities fraud between November 4, 2024, and October 3, 2025. The case is being handled by the law firm Levi & Korsinsky, which has a history of representing shareholders in complex securities litigation. Investors affected during the specified period are encouraged to seek information about their rights and potential recovery options.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief via ACCESS Newswire  on December 23, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDL95n2z3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SKYE"],"gpt_icon":0},{"id":"2592194201","title":"Skye Bioscience Faces Class Action Lawsuit Over Securities Fraud Allegations","url":"https://stock-news.laohu8.com/highlight/detail?id=2592194201","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592194201?lang=en_us&edition=fundamental","pubTime":"2025-12-20 03:42","pubTimestamp":1766173336,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against Skye Bioscience Inc., alleging securities fraud that affected investors between November 4, 2024, and October 3, 2025. The lawsuit claims that shareholders suffered financial losses as a result of the company’s actions during this period. Investors who experienced losses are encouraged to seek information about their legal rights and potential remedies. The case is being handled by the law firm Levi & Korsinsky, which has a significant track record in securities litigation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief via ACCESS Newswire  on December 19, 2025, and is solely responsible for the information","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL8HQNBx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2590537288","title":"Skye Bioscience Faces Investor Class Action Over Securities Fraud Allegations","url":"https://stock-news.laohu8.com/highlight/detail?id=2590537288","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590537288?lang=en_us&edition=fundamental","pubTime":"2025-12-11 03:47","pubTimestamp":1765396037,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against Skye Bioscience Inc., alleging securities fraud that affected investors who purchased shares between November 4, 2024, and October 3, 2025. The legal action claims that shareholders suffered financial losses due to the company's alleged misconduct. The case is being handled by the law firm Levi & Korsinsky, which has a history of representing investors in securities litigation and has secured significant recoveries for clients in previous cases. Investors who suffered losses during the specified period are encouraged to seek information about their rights and potential participation in the lawsuit.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original co","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL6Q2QZj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SKYE"],"gpt_icon":0},{"id":"2585461547","title":"Skye Bioscience Unveils Presentation Highlighting Nimacimab’s Potential to Enhance Obesity Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2585461547","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585461547?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:04","pubTimestamp":1763985851,"startTime":"0","endTime":"0","summary":"Skye Bioscience Inc. has provided an update on the development of nimacimab, a novel therapeutic candidate for obesity and metabolic diseases. According to the presentation, nimacimab is positioned as a complementary treatment to existing GLP-1 therapies, offering approximately 3% additional weight loss when used in combination with semaglutide over 26 weeks. The data also indicate a lower rate of post-treatment weight rebound and a favorable body composition profile compared to GLP-1 monotherapy. The company highlights nimacimab's differentiated peripheral CB1 mechanism, which does not increase gastrointestinal or neuropsychiatric adverse events in combination regimens. Skye Bioscience reports a clear pharmacokinetic and exposure-response profile from Phase 2a studies and is planning further evaluation at higher doses. Nimacimab is presented as suitable for both patients who do not respond to or tolerate GLP-1 therapies and for those seeking enhanced weight loss outcomes. You can acce","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL8JPPYQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2585615834","title":"Skye Bioscience to Participate in Major Healthcare Investment Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2585615834","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585615834?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:01","pubTimestamp":1763985661,"startTime":"0","endTime":"0","summary":"Skye Bioscience Inc. will participate in several upcoming investment conferences, including the Citi Global Healthcare Conference in Miami with 1x1 meetings on December 2, the Evercore Annual Healthcare Conference in Coral Gables featuring a fireside chat on December 3 at 12:55 pm ET and 1x1 meetings, and the Piper Sandler Annual Healthcare Conference in New York with a fireside chat on December 4 at 11:30 am ET and 1x1 meetings. Webcasts of the events will be available on Skye's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief via Newsfile  on November 24, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDLbnvhXW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4127","LU2417539215.USD","LU2456880835.USD","LU1201861249.SGD","LU0320765646.SGD","LU0106831901.USD","BK4566","LU0648001328.SGD","LU1244550494.USD","LU1267930227.SGD","LU2462157665.USD","LU0130517989.USD","EVR","PIPR","LU0477156953.USD","LU0162691827.USD","LU0128525689.USD","LU2125154778.USD","LU1162221912.USD","LU2236285917.USD","BK4534","LU1668664300.SGD","LU0130102774.USD","LU0072461881.USD","BK4585","LU0170899867.USD","BK4559","LU2125154935.USD","LU2360032135.SGD","SKYE","BK4139","LU0098860793.USD","LU0310800965.SGD","LU1366192091.USD","LU1791807156.HKD","LU0052756011.USD","BK4588","LU1244550221.USD","BK4504","BK4207","IE00BSNM7G36.USD","LU0980610538.SGD","LU1244550577.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.skyebioscience.com","stockEarnings":[{"period":"1week","weight":0.02},{"period":"1month","weight":0.275},{"period":"3month","weight":-0.3462},{"period":"6month","weight":-0.7175},{"period":"1year","weight":-0.6331},{"period":"ytd","weight":0.3605}],"compareEarnings":[{"period":"1week","weight":0.0015},{"period":"1month","weight":0.0035},{"period":"3month","weight":0.0083},{"period":"6month","weight":0.0918},{"period":"1year","weight":0.1394},{"period":"ytd","weight":0.0159}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.8,"avgChangeRate":0.395123},{"month":2,"riseRate":0.4,"avgChangeRate":0.538593},{"month":3,"riseRate":0.4,"avgChangeRate":-0.146364},{"month":4,"riseRate":0.4,"avgChangeRate":-0.005682},{"month":5,"riseRate":0.6,"avgChangeRate":0.011057},{"month":6,"riseRate":0.6,"avgChangeRate":0.270302},{"month":7,"riseRate":0.4,"avgChangeRate":-0.080829},{"month":8,"riseRate":0.2,"avgChangeRate":-0.076771},{"month":9,"riseRate":0.2,"avgChangeRate":-0.127741},{"month":10,"riseRate":0.2,"avgChangeRate":-0.245291},{"month":11,"riseRate":0.2,"avgChangeRate":-0.107928},{"month":12,"riseRate":0.2,"avgChangeRate":-0.107415}],"exchange":"NASDAQ","name":"Skye Bioscience Inc.","nameEN":"Skye Bioscience Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Skye Bioscience Inc.(SKYE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Skye Bioscience Inc.(SKYE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Skye Bioscience Inc.,SKYE,Skye Bioscience Inc.股票,Skye Bioscience Inc.股票老虎,Skye Bioscience Inc.股票老虎国际,Skye Bioscience Inc.行情,Skye Bioscience Inc.股票行情,Skye Bioscience Inc.股价,Skye Bioscience Inc.股市,Skye Bioscience Inc.股票价格,Skye Bioscience Inc.股票交易,Skye Bioscience Inc.股票购买,Skye Bioscience Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Skye Bioscience Inc.(SKYE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Skye Bioscience Inc.(SKYE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction